Healthcare Realty Trust Reports Annual Results, Significant Debt Reduction, and New Capital Initiatives
Summary
Healthcare Realty Trust filed its 2025 annual report, highlighting a significant reduction in debt, improved FFO and FAD, and new capital initiatives including a $500 million share repurchase authorization and a $1 billion ATM program.
Key Events
-
Significant Debt Reduction
The company reduced its total outstanding indebtedness (principal balance) by approximately $600 million in 2025, from $4.7 billion in 2024 to $4.1 billion. This includes the repayment of $300 million, $200 million, and $150 million unsecured term loans.
-
Improved Financial Performance Metrics
FFO attributable to common stockholders increased significantly to $490.0 million in 2025 from $193.3 million in 2024. FAD also increased to $448.3 million in 2025 from $419.1 million in 2024. Same Store Cash NOI increased to $601.9 million in 2025 from $573.1 million in 2024.
-
Enhanced Capital Flexibility
The revolving credit facility was extended to July 25, 2029, with two six-month extension options. A new commercial paper program was established in January 2026, allowing for up to $600 million in short-term notes, backed by the unsecured credit facility.
-
Increased Share Repurchase Authorization
The Board authorized a new $500 million share repurchase program on October 28, 2025, superseding the previous $300 million authorization. In January 2026, the company repurchased 2.9 million shares for $50.0 million under this program.
Analysis
Healthcare Realty Trust's 2025 annual report details a substantial reduction in outstanding debt, improved FFO and FAD, and strategic capital management initiatives. While the company recorded significant real estate impairment charges, these were offset by gains on property sales and a lack of goodwill impairment in 2025, contrasting with the prior year. The extension of the revolving credit facility and the new commercial paper program enhance liquidity and financial flexibility. The increased share repurchase authorization signals confidence in the company's valuation. Investors should monitor the impact of the new ATM program on potential dilution and the company's ability to re-let remaining space from the Prospect Medical bankruptcy.
At the time of this filing, HR was trading at $17.96 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $14.09 to $18.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.